However, in the ICI‐chemotherapy combination group, anti‐PD1 was associated with a trend to better ORR compared with anti‐PD‐L1 as first‐line therapy for NSCLC (p = 0.12). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.